KRAS and neoplasm: Tumor subtyping, genomic profiling, genomic analysis for mutations in DNA damage repair pathways (BRCA1, BRCA2, KRAS, HER2, PALB2, ATM; IMPaCt trial), next-generation DNA and RNA sequencing to investigate the changing genomic landscape, characterizing post-transcriptional epigenetic regulation through miRNA and lnRNA regulating tumor growth are other potential strategies which should be focused on to develop targeted and personalized medicine.